Global Pulmonary Hypertension Drugs Market Study 2016-2026, by Segment (Prostacyclin and prostacyclin analogs , Endothelin receptor antagonists (ERAs) , … …), by Market (Early-stage Drug Candidates (Phase I & Phase II), Late-stage Drug Candidat
SKU ID :99ST-14631989 | Published Date: 29-Oct-2019 | No. of pages: 45Description
Summary
The global Pulmonary Hypertension Drugs market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Prostacyclin and prostacyclin analogs
Endothelin receptor antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) inhibitors
Soluble guanylate cyclase (sGC) stimulators
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
Bayer
GSK
Arena
Actelion
Pfizer
United Therapeutics
Gilead Sciences
Lung Biotechnology PBC
North America
Europe
Asia-Pacific
South America
Middle East & Africa
The global Pulmonary Hypertension Drugs market will reach Volume Million USD in 2019 and with a CAGR xx% between 2020-2026.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Prostacyclin and prostacyclin analogs
Endothelin receptor antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) inhibitors
Soluble guanylate cyclase (sGC) stimulators
Demand Coverage (Market Size & Forecast, Consumer Distribution):
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
Company Coverage (Sales data, Main Products & Services etc.):
Bayer
GSK
Arena
Actelion
Pfizer
United Therapeutics
Gilead Sciences
Lung Biotechnology PBC
Major Region
MarketNorth America
Europe
Asia-Pacific
South America
Middle East & Africa
TOC
Tables & Figures
Companies
- PRICE
-
$1800$3600Buy Now